Comparative Pharmacology
Head-to-head clinical analysis: LOXITANE IM versus QUIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXITANE IM versus QUIDE.
LOXITANE IM vs QUIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOXITANE IM (loxapine) is a dibenzoxazepine antipsychotic. Its mechanism of action is not fully established but is thought to be mediated via antagonism of central dopamine D2 and serotonin 5-HT2A receptors. It has high affinity for D2, D3, D4, and 5-HT2A receptors and low affinity for D1 receptors. It also has moderate affinity for histamine H1 and alpha1-adrenergic receptors.
Quetiapine acts as an antagonist at multiple neurotransmitter receptors in the brain, including serotonin 5-HT2A, dopamine D2, histamine H1, and adrenergic α1 receptors. It also has partial agonist activity at serotonin 5-HT1A receptors. This atypical antipsychotic action is mediated primarily through 5-HT2A and D2 antagonism.
Adults: 12.5-50 mg IM every 4-6 hours as needed, not to exceed 150 mg/day.
5 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours. Clinically, steady-state reached in 2-3 days; dosing interval based on q6-12h.
2-4 hours (prolonged in renal impairment, requiring dose adjustment)
Primarily renal: 70% as metabolites; biliary/fecal: 30% as metabolites and unchanged drug.
Primarily renal (80% as unchanged drug); minor fecal (20%)
Category C
Category C
Antipsychotic
Antipsychotic